These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

828 related items for PubMed ID: 30910320

  • 1. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
    Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Calleja JL, Aracil C, Bañares R, Morillas RM, Poca M, Peñas B, Augustin S, Abraldes JG, Alvarado E, Torres F, Bosch J.
    Lancet; 2019 Apr 20; 393(10181):1597-1608. PubMed ID: 30910320
    [Abstract] [Full Text] [Related]

  • 2. Carvedilol to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by liver stiffness: study protocol for a randomied, double-blind, placebo-controlled, multicentre trial in China.
    Liu C, Zhang L, Zhang S, Li X, Wong YJ, Liang X, Wang Y, Wu X, Gou W, Lv J, Hu S, Fu J, Huang J, Ge G, Huang M, Wang F, Zhang Q, Ren T, Meng Z, Ding D, Zhuoga B, Zhuoga C, Fan J, Dang D, Miao L, Song Z, Xiao X, Wu H, Jiang K, Liu T, Gao Y, Ma L, Fang T, Wang Y, Zhang Q, Zhu D, Ji D, Cao Z, Zeng QL, Li J, Chen P, Wei Y, Tong Z, Hong Z, Liang X, Li Y, Nan Y, Qi X.
    BMJ Open; 2024 Jul 11; 14(7):e081623. PubMed ID: 38991669
    [Abstract] [Full Text] [Related]

  • 3. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.
    Villanueva C, Torres F, Sarin SK, Shah HA, Tripathi D, Brujats A, Rodrigues SG, Bhardwaj A, Azam Z, Hayes PC, Jindal A, Abid S, Alvarado E, Bosch J, Carvedilol-IPD-MA-group and the Baveno Cooperation: an EASL Consortium.
    J Hepatol; 2022 Oct 11; 77(4):1014-1025. PubMed ID: 35661713
    [Abstract] [Full Text] [Related]

  • 4. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
    Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS, Bosch J, Portal Hypertension Collaborative Group.
    Gastroenterology; 2007 Aug 11; 133(2):481-8. PubMed ID: 17681169
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of oesophageal varices: study protocol for a randomised controlled trial.
    Patel VC, McPhail MJ, Uddin R, Jafari H, Lawrence V, Le Boutillier C, Shearer J, Yaziji N, Cape A, Ahmed H, Ward C, Walsh P, Besly K, Zamalloa A, Kelly J, BOPPP study group, Carter B.
    Trials; 2024 Apr 16; 25(1):265. PubMed ID: 38627804
    [Abstract] [Full Text] [Related]

  • 8. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices.
    Zacharias AP, Jeyaraj R, Hobolth L, Bendtsen F, Gluud LL, Morgan MY.
    Cochrane Database Syst Rev; 2018 Oct 29; 10(10):CD011510. PubMed ID: 30372514
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The portal hypertension syndrome: etiology, classification, relevance, and animal models.
    Bosch J, Iwakiri Y.
    Hepatol Int; 2018 Feb 29; 12(Suppl 1):1-10. PubMed ID: 29064029
    [Abstract] [Full Text] [Related]

  • 11. A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis.
    Villanueva C, Graupera I, Aracil C, Alvarado E, Miñana J, Puente Á, Hernandez-Gea V, Ardevol A, Pavel O, Colomo A, Concepción M, Poca M, Torras X, Reñe JM, Guarner C.
    Hepatology; 2017 May 29; 65(5):1693-1707. PubMed ID: 28100019
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
    Garcia-Tsao G, Bosch J, Kayali Z, Harrison SA, Abdelmalek MF, Lawitz E, Satapathy SK, Ghabril M, Shiffman ML, Younes ZH, Thuluvath PJ, Berzigotti A, Albillos A, Robinson JM, Hagerty DT, Chan JL, Sanyal AJ, IDN-6556-14 Investigators(‡).
    J Hepatol; 2020 May 29; 72(5):885-895. PubMed ID: 31870950
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol.
    Reiberger T, Ulbrich G, Ferlitsch A, Payer BA, Schwabl P, Pinter M, Heinisch BB, Trauner M, Kramer L, Peck-Radosavljevic M, Vienna Hepatic Hemodynamic Lab.
    Gut; 2013 Nov 29; 62(11):1634-41. PubMed ID: 23250049
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis.
    Kim SG, Kim TY, Sohn JH, Um SH, Seo YS, Baik SK, Kim MY, Jang JY, Jeong SW, Lee B, Kim YS, Suk KT, Kim DJ.
    Am J Gastroenterol; 2016 Nov 29; 111(11):1582-1590. PubMed ID: 27575713
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Influence of further decompensation on survival across clinical stages of decompensated cirrhosis: The role of portal hypertension and HVPG changes.
    Garcia-Guix M, Ardevol A, Sapena V, Alvarado-Tápias E, Huertas A, Brujats A, Fajardo J, Cuyas B, Poca M, Guarner C, Torras X, Escorsell À, Villanueva C.
    Liver Int; 2024 Aug 29; 44(8):1971-1989. PubMed ID: 38634685
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.